STAAR Surgical Announces Submission of Presbyopia Clinical Trial Data; Proprietary EDOF Collamer® Lens is Designed to Improve Near, Intermediate and Distance Vision

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to STAAR Surgical Announces Submission of Presbyopia Clinical Trial Data; Proprietary EDOF Collamer® Lens is Designed to Improve Near, Intermediate and Distance Vision

STAAR Surgical (STAA) Tops Q2 EPS by 4c, Slight Beat on Revenues

July 31, 2019 5:33 PM EDT

STAAR Surgical (NASDAQ: STAA) reported Q2 EPS of $0.08, $0.04 better than the analyst estimate of $0.04. Revenue for the quarter came in at $39.7 million versus the consensus estimate of $39.13 million.

Second Quarter 2019 Overview

Net Sales of $39.7 Million (Up 17%) as Reported and $40.3 Million (Up 19%) Constant Currency from the Prior Year QuarterICL Sales of $34.4 Million (Up 26%) as Reported and $34.9 Million (Up 28%) Constant Currency from the Prior Year QuarterICL Units Up 34% from the Prior Year QuarterGross Margin at 75.4% Up 100 Basis Points from the Prior Year QuarterNet Income... More